Delivery Order SPE2DR25D3017-SPE2DR26F3EP1
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $36,129.49 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors. This competitively awarded, firm fixed-price delivery order was issued on November 14, 2025, with an ultimate completion date of November 17, 2025. The contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency has awarded a $12,054.16 delivery order to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injectors. This competitively awarded, firm fixed-price delivery order was issued on December 1, 2025, with an ultimate completion date of December 2, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting the company's demonstrated...
- The Defense Logistics Agency awarded a $11,589.48 delivery order to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of December 4, 2025. This competitive award, issued without set-aside designation, represents a firm fixed-price delivery order under AmerisourceBergen's existing indefinite delivery contract vehicle with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $22,421.56 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injectors. This firm fixed-price, non-set-aside delivery order was awarded on November 24, 2025, with an ultimate completion date of November 25, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Repatha is a prescription medication used to treat high cholesterol in patients at risk...
- The Defense Logistics Agency awarded a $27,169.36 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors on November 24, 2025, with completion targeted for November 25, 2025. This firm fixed price, non-set-aside delivery order represents a single transaction under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The product will be delivered to the vendor's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $12,168.64 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of November 21, 2025. This is a firm fixed-price delivery order with no set-aside designation, performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a competitive procurement action on behalf of federal military and healthcare systems. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $9,099.77 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors on November 13, 2025, with completion scheduled for November 14, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a small single-transaction order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The product will be delivered to the...
- The Defense Logistics Agency awarded a $28,440.68 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pharmaceutical products. The contract, executed on December 2, 2025, with an ultimate completion date of December 3, 2025, utilizes firm fixed-price pricing and carries no set-aside designation, indicating competitive award based on AmerisourceBergen's demonstrated capability to meet federal procurement requirements. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $9,570.07 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of October 21, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor's corporate office located in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's existing contract vehicle for pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $6,948.71 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of November 5, 2025. This non-competitive, firm fixed-price delivery order was issued on November 4, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with DLA's Medical...
- SPE2DR25D3017Indefinite Delivery Contract
- SPE2DR25D3017-SPE2DR26F3EP1Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $44,057.98 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injectors. This non-set-aside, firm fixed-price delivery order was competitively awarded on December 11, 2025, with an ultimate completion date of December 12, 2025. The pharmaceutical products will be supplied from AmerisourceBergen's facility in Conshohocken, Pennsylvania, supporting federal medical supply chain requirements. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide. Repatha is a PCSK9 inhibitor used for managing high cholesterol in patients at risk for cardiovascular disease, consistent with AmerisourceBergen's extensive portfolio of specialty medications, brand-name and generic drugs, and medical supplies delivered across multiple therapeutic domains to federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $44.1k | 12/10/25 |